Anti-programmed death ligand 1 therapy-induced type 1 diabetes presenting with multiple islet-related autoantibodies

J Diabetes Investig. 2020 Jan;11(1):253-254. doi: 10.1111/jdi.13099. Epub 2019 Jul 8.

Authors

Affiliations

¹ 1st Department of Internal Medicine, University of Toyama, Toyama, Japan.
² Medical Research Management Center, University of Toyama, Toyama, Japan.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects
Autoantibodies / blood
Autoantibodies / immunology*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology
Biomarkers / analysis
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
Diabetes Mellitus, Type 1 / chemically induced
Diabetes Mellitus, Type 1 / immunology*
Diabetes Mellitus, Type 1 / pathology
Glutamate Decarboxylase / immunology*
Humans
Islets of Langerhans / drug effects
Islets of Langerhans / immunology*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Prognosis

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Autoantibodies
B7-H1 Antigen
Biomarkers
CD274 protein, human
atezolizumab
Glutamate Decarboxylase